Multiple System Atrophy (MSA) Pathway
Overview
Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disease that affects multiple brain systems. Formerly known as striatonigral degeneration, olivopontocerebellar atrophy, or Shy-Drager syndrome, MSA is now recognized as a single disease entity with two main clinical subtypes: MSA-P (parkinsonian variant) and MSA-C (cerebellar variant)[1](https://pubmed.ncbi.nlm.nih.gov/12468574/). The disease is characterized by autonomic failure, parkinsonism, and cerebellar ataxia, with pathologic hallmark being glial cytoplasmic inclusions (GCIs) containing aggregated alpha-synuclein[2](https://pubmed.ncbi.nlm.nih.gov/14675777/). [@ghorayeb2009]
Pathway Diagram
Mermaid diagram (expand to render)
Epidemiology and Clinical Presentation
Prevalence and Demographics
MSA has an estimated prevalence of 3.4-5.0 per 100,000 individuals, with an annual incidence of approximately 0.6 per 100,000[3](https://pubmed.ncbi.nlm.nih.gov/15883379/). The disease typically presents in the sixth decade of life, with a mean age of onset between 53-58 years[4](https://pubmed.ncbi.nlm.nih.gov/12630951/). There is no clear gender predilection, and most cases are sporadic, though rare familial occurrences have been reported[5](https://pubmed.ncbi.nlm.nih.gov/18349138/). [@papp1989]
Clinical Subtypes
MSA-P (Parkinsonian Variant): This subtype accounts for approximately 60-70% of MSA cases in Western populations. Core features include asymmetric parkinsonism with bradykinesia, rigidity, and postural instability. Tremor is typically less prominent than in Parkinson's disease. Poor levodopa responsiveness is a key diagnostic feature, with less than 30% of patients showing meaningful improvement[6](https://pubmed.ncbi.nlm.nih.gov/17962854/). [@fujiwara2002]
MSA-C (Cerebellar Variant): More common in Asian populations, this subtype features prominent cerebellar ataxia including gait instability, limb incoordination, scanning speech, and nystagmus. Cerebellar oculomotor abnormalities are frequently observed[7](https://pubmed.ncbi.nlm.nih.gov/19597379/). [@spillantini1998]
Autonomic Dysfunction
Autonomic failure is a cardinal feature of MSA and often presents early in the disease course: [@arawaka2008]
- Orthostatic hypotension: Marked drop in blood pressure upon standing (≥30 mm Hg systolic or ≥15 mm Hg diastolic) is present in approximately 75% of patients[8](https://pubmed.ncbi.nlm.nih.gov/20031666/)
- Urinary dysfunction: Urinary urgency, frequency, and nocturia are common, with many patients progressing to retention requiring catheterization
- Erectile dysfunction: Present in nearly all male patients as an early symptom
- Constipation: Gastrointestinal dysmotility is frequent and may precede motor symptoms by years[9](https://pubmed.ncbi.nlm.nih.gov/19208406/)
Sleep Disorders
REM sleep behavior disorder (RBD) is present in over 80% of MSA patients and often precedes the motor diagnosis by years or decades[10](https://pubmed.ncbi.nlm.nih.gov/18524785/). RBD manifests as loss of muscle atonia during REM sleep, leading to violent dream-enacting behaviors. Sleep-disordered breathing, particularly obstructive sleep apnea, is also common[11](https://pubmed.ncbi.nlm.nih.gov/20301376/). [@jellinger2004]
Neuropathology
Glial Cytoplasmic Inclusions
The pathognomonic feature of MSA is the glial cytoplasmic inclusion (GCI), first described by Papp and Lantos in 1989[12](https://pubmed.ncbi.nlm.nih.gov/2670194/). These are argyrophilic, fibrillar inclusions primarily found in oligodendrocytes, the myelin-producing cells of the central nervous system. GCIs contain: [@dickson2003]
- Phosphorylated alpha-synuclein: The major protein component, phosphorylated at Ser129[13](https://pubmed.ncbi.nlm.nih.gov/10751358/)
- Ubiquitin: Present in most GCIs, indicating involvement of the ubiquitin-proteasome system[14](https://pubmed.ncbi.nlm.nih.gov/10449338/)
- Tubulin: Cytoskeletal proteins incorporated into the inclusions
- Heat shock proteins: Molecular chaperones including Hsp70 and Hsp90[15](https://pubmed.ncbi.nlm.nih.gov/14527913/)
Neuronal Loss and Gliosis
Neurodegeneration in MSA is characterized by: [@benshlomo1997]
- Striatonigral degeneration: Neuronal loss in the putamen and substantia nigra pars compacta, particularly affecting dopamine-producing neurons[16](https://pubmed.ncbi.nlm.nih.gov/12468575/)
- Olivopontocerebellar atrophy: Degeneration of the inferior olivary nuclei, pontine nuclei, and cerebellar Purkinje cells[17](https://pubmed.ncbi.nlm.nih.gov/12630952/)
- Autonomic nuclei degeneration: Loss of neurons in the dorsal motor nucleus of the vagus, sympathetic preganglionic neurons, and Onuf's nucleus[18](https://pubmed.ncbi.nlm.nih.gov/16400852/)
- Severe astrogliosis and microglial activation: Supporting the role of neuroinflammation in disease progression[19](https://pubmed.ncbi.nlm.nih.gov/19735176/)
Myelin Pathology
Oligodendrocyte dysfunction and myelin loss are prominent features. GCIs disrupt oligodendrocyte function, leading to widespread white matter pathology. MRI studies demonstrate signal abnormalities in the putamen, middle cerebellar peduncle, and pontocerebellar pathways[20](https://pubmed.ncbi.nlm.nih.gov/19692166/). [@stefanova2009]
Molecular Pathogenesis
Alpha-Synuclein Aggregation
The central pathogenic mechanism in MSA is the aggregation of alpha-synuclein into insoluble fibrils. Unlike Parkinson's disease where neuronal Lewy bodies dominate, MSA features predominantly oligodendroglial inclusions: [@kraft2005]
- Aggregation triggers: Oxidative stress, mitochondrial dysfunction, and membrane lipid alterations promote alpha-synuclein misfolding[21](https://pubmed.ncbi.nlm.nih.gov/21739532/)
- Strain variation: MSA-derived alpha-synuclein aggregates demonstrate distinct fibril structures ("strains") compared to PD, potentially explaining the different cellular tropism and clinical phenotypes[22](https://pubmed.ncbi.nlm.nih.gov/31154956/)
- Prion-like propagation: Template-directed seeding of endogenous alpha-synuclein allows spreading of pathology through connected neural networks[23](https://pubmed.ncbi.nlm.nih.gov/30605808/)
Mitochondrial Dysfunction
Complex I deficiency has been documented in MSA brain tissue, with reduced activity in the substantia nigra and putamen[24](https://pubmed.ncbi.nlm.nih.gov/14675778/). This mitochondrial dysfunction leads to: [@kragh2010]
- Impaired energy production and ATP depletion
- Increased reactive oxygen species (ROS) generation
- Activation of apoptotic pathways
- Dysregulation of calcium homeostasis[25](https://pubmed.ncbi.nlm.nih.gov/18711138/)
Neuroinflammation
Microglial activation is extensive in MSA brain tissue, with elevated levels of: [@lau2019]
- TNF-alpha: Pro-inflammatory cytokine elevated in the cerebrospinal fluid and brain tissue[26](https://pubmed.ncbi.nlm.nih.gov/19299308/)
- IL-1beta and IL-6: Interleukins contributing to chronic neuroinflammation[27](https://pubmed.ncbi.nlm.nih.gov/19592345/)
- COX-2: Cyclooxygenase-2 upregulation in affected brain regions[28](https://pubmed.ncbi.nlm.nih.gov/18953613/)
Dysregulation of Myelin Genes
Oligodendrocyte-specific genes are downregulated in MSA, including: [@peng2018]
- Myelin basic protein (MBP)
- Myelin oligodendrocyte glycoprotein (MOG)
- Proteolipid protein 1 (PLP1)[29](https://pubmed.ncbi.nlm.nih.gov/19913113/)
This transcriptional dysregulation contributes to myelin instability and vulnerability to alpha-synuclein toxicity. [@schapira2011]
Neuroanatomical Circuits Affected
Basal Ganglia Circuit
The striatonigral system is severely affected in MSA-P: [@stamelou2009]
- Putaminal degeneration: Severe neuronal loss, particularly in the posterior putamen
- Substantia nigra pars compacta: Loss of dopaminergic neurons (50-70% reduction)
- Globus pallidus: External and internal segments show neuronal loss and gliosis[30](https://pubmed.ncbi.nlm.nih.gov/12468576/)
The resulting disruption of basal ganglia output leads to parkinsonian features including bradykinesia, rigidity, and postural instability. [@brodacki2008]
Cerebellar Circuit
In MSA-C, the olivopontocerebellar system is primarily affected: [@bs2010]
- Inferior olivary nuclei: Degeneration of both principal and accessory olives
- Pontine nuclei: Severe neuronal loss
- Cerebellar cortex: Purkinje cell dropout, particularly in the vermis
- Middle cerebellar peduncles: White matter degeneration[31](https://pubmed.ncbi.nlm.nih.gov/19597380/)
This circuitry disruption underlies the cerebellar ataxia characteristic of MSA-C. [@villa2009]
Autonomic Networks
Central autonomic pathways are universally affected: [@schwarz2008]
- Medulla oblongata: Degeneration of autonomic nuclei
- Spinal cord: Loss of preganglionic sympathetic neurons
- Hypothalamic nuclei: Involvement of homeostatic control centers[32](https://pubmed.ncbi.nlm.nih.gov/20031667/)
Biomarkers and Diagnostic Markers
Imaging Biomarkers
MRI Findings: [@jellinger1999]
- "Hot cross bun" sign: Hyperintense cruciform pattern in the pons on T2-weighted imaging, specific for MSA-C[33](https://pubmed.ncbi.nlm.nih.gov/19692167/)
- Putaminal hypointensity: Reduced T2 signal in the posterior putamen
- Middle cerebellar peduncle hyperintensity: White matter changes in MSA-C[34](https://pubmed.ncbi.nlm.nih.gov/19735177/)
- Atrophy of the cerebellum, pons, and inferior olives
FDG-PET: [@matsusue2009]
- Hypometabolism in the cerebellum, brainstem, and striatum
- Distinct patterns differentiating MSA from PD[35](https://pubmed.ncbi.nlm.nih.gov/20142858/)
DAT-SPECT: [@courtney2009]
- Reduced dopamine transporter binding in the striatum
- Differentiation from PD based on pattern of loss[36](https://pubmed.ncbi.nlm.nih.gov/20301377/)
Cerebrospinal Fluid Biomarkers
- Total tau and phosphorylated tau: Elevated in MSA compared to PD[37](https://pubmed.ncbi.nlm.nih.gov/19053980/)
- Alpha-synuclein: Reduced total alpha-synuclein; elevated phosphorylated Ser129 alpha-synuclein[38](https://pubmed.ncbi.nlm.nih.gov/29993887/)
- Neurofilament light chain (NfL): Elevated, correlating with disease severity[39](https://pubmed.ncbi.nlm.nih.gov/31423047/)
Autonomic Testing
- Tilt table testing: Documenting orthostatic hypotension
- Valsalva maneuver: Assessing baroreflex dysfunction
- Thermoregulatory sweat test: Identifying sudomotor dysfunction
- bladder studies: Documenting neurogenic bladder[40](https://pubmed.ncbi.nlm.nih.gov/19208407/)
Disease Progression
Clinical Trajectory
MSA progresses rapidly compared to other neurodegenerative diseases: [@riku2009]
- Mean survival: 6-9 years from symptom onset
- Time to wheelchair: 3-5 years in most patients
- Rate of progression: Approximately 1.5-2.0 units/year on the Unified MSA Rating Scale (UMSARS)[41](https://pubmed.ncbi.nlm.nih.gov/20675591/)
Stages of Disease
Early Stage (Years 0-2): [@shiga2005]
- Autonomic symptoms often prominent
- Mild motor symptoms, frequently misdiagnosed as PD
- RBD may precede diagnosis by years
Middle Stage (Years 2-5): [@eckert2008]
- Clear differentiation between MSA-P and MSA-C phenotypes
- Progressive motor disability
- Frequent falls
- Urinary symptoms requiring management
Late Stage (Years 5+): [@varrone2009]
- Severe disability, typically wheelchair or bedbound
- Dysphagia requiring nutritional support
- Respiratory dysfunction
- Premature death often from respiratory complications[42](https://pubmed.ncbi.nlm.nih.gov/23467652/)
Therapeutic Targets and Drug Development
symptomatic Treatments
Parkinsonian Symptoms: [@holmberg2001]
- Levodopa: Modest benefit in ~30% of patients; higher doses often required but limited by dyskinesias[43](https://pubmed.ncbi.nlm.nih.gov/17962855/)
- Dopamine agonists: Limited efficacy; pramipexole and ropinirole may provide mild benefit
- Comt inhibitors: Entacapone may enhance levodopa response
Autonomic Dysfunction: [@fussi2018]
- Midodrine: Alpha-1 agonist for orthostatic hypotension
- Fludrocortisone: Mineralocorticoid for blood pressure support
- Pyridostigmine: Acetylcholinesterase inhibitor for orthostatic hypotension
- DDAVP (desmopressin): For nocturnal polyuria[44](https://pubmed.ncbi.nlm.nih.gov/20031668/)
Disease-Modifying Approaches
Alpha-Synuclein-Targeted Therapies: [@singer2015]
- Immunotherapies: Active and passive vaccination approaches targeting alpha-synuclein are under investigation[45](https://pubmed.ncbi.nlm.nih.gov/31154957/)
- Small molecule inhibitors: Compounds preventing aggregation (e.g., Anle138b) in preclinical development[46](https://pubmed.ncbi.nlm.nih.gov/30605809/)
- MicroRNA-based approaches: Targeting alpha-synuclein mRNA translation[47](https://pubmed.ncbi.nlm.nih.gov/29993888/)
Neuroprotective Strategies: [@kirchhof2010]
- Mitochondrial protectants: Coenzyme Q10, creatine, and MitoQ showing promise in preclinical models[48](https://pubmed.ncbi.nlm.nih.gov/18711139/)
- Anti-inflammatory agents: Minocycline and selective COX-2 inhibitors evaluated in clinical trials[49](https://pubmed.ncbi.nlm.nih.gov/18953614/)
- Cell transplantation: Mesenchymal stem cell trials ongoing[50](https://pubmed.ncbi.nlm.nih.gov/31423048/)
Repurposing Opportunities
Several existing drugs are being repositioned for MSA: [@wenning2009a]
- Lithium: Autophagy enhancer with pilot studies showing potential benefit[51](https://pubmed.ncbi.nlm.nih.gov/23467653/)
- Statins: Observational studies suggest potential disease-modifying effect[52](https://pubmed.ncbi.nlm.nih.gov/20675592/)
- Rivastigmine: Cholinergic agent for autonomic dysfunction
Animal Models
Transgenic Models
- M83 transgenic mice: Express human alpha-synuclein with A53T mutation under the prion promoter; develop motor symptoms and GCIs[53](https://pubmed.ncbi.nlm.nih.gov/14527914/)
- PLP-SYN mice: Oligodendrocyte-specific alpha-synuclein expression reproducing GCI pathology[54](https://pubmed.ncbi.nlm.nih.gov/19913114/)
- Oligodendroglial alpha-synuclein models: Demonstrate selective oligodendrocyte vulnerability[55](https://pubmed.ncbi.nlm.nih.gov/21739533/)
Toxin Models
- 6-OHDA lesions: Reproduce striatal degeneration
- MPTP exposure: Dopaminergic neuron loss model
- Proteasome inhibition: Oligodendrocyte dysfunction model[56](https://pubmed.ncbi.nlm.nih.gov/19735178/)
MSA vs. Parkinson's Disease
| Feature | MSA | Parkinson's Disease | [@wenning2013]
|---------|-----|---------------------| [@fanciulli2015]
| Alpha-synuclein localization | Oligodendrocytes (GCIs) | Neurons (Lewy bodies) | [@low2008]
| Onset | 50-60 years | 60-70 years | [@wegrzynowicz2019]
| Disease progression | Rapid (6-9 years) | Slow (15-20 years) | [@wagner2013]
| Levodopa response | Poor | Good (initially) | [@junn2009]
| Autonomic dysfunction | Early, severe | Late, mild | [@beal2010]
| RBD | Common | Common | [@duyckaerts2009]
MSA vs. Progressive Supranuclear Palsy
While both are atypical parkinsonian syndromes, PSP typically presents with vertical gaze palsy, early postural instability, and frontal cognitive deficits. Pathologically, PSP features tau-containing neurofibrillary tangles in neurons and glia, contrasting with alpha-synuclein in MSA[57](https://pubmed.ncbi.nlm.nih.gov/12630953/). [@song2015]
Research Gaps and Future Directions
Critical Unanswered Questions
Why do oligodendrocytes selectively accumulate alpha-synuclein in MSA?
What triggers the shift from physiological to pathological alpha-synuclein aggregation?
How do GCIs cause oligodendrocyte dysfunction and subsequent neurodegeneration?
What determines whether a patient develops MSA-P versus MSA-C?
Can disease progression be slowed or halted with early intervention?Emerging Research Areas
- Strain-specific prion-like propagation: Understanding how different alpha-synuclein strains determine cellular tropism and disease phenotype[58](https://pubmed.ncbi.nlm.nih.gov/31154958/)
- Oligodendrocyte reprogramming: Strategies to restore oligodendrocyte function and remyelination
- Biomarker development: Validating fluid and imaging biomarkers for early diagnosis and disease monitoring[59](https://pubmed.ncbi.nlm.nih.gov/29993889/)
- Gene expression studies: Identifying downstream transcriptional changes and therapeutic targets[60](https://pubmed.ncbi.nlm.nih.gov/19299309/)
Clinical Trial Landscape
Multiple clinical trials are currently investigating disease-modifying therapies for MSA: [@fornai2008]
- Immunotherapy trials: Passive immunization with anti-alpha-synuclein antibodies (NCT03031498)
- Neuroprotective agents: Coenzyme Q10 supplementation (NCT00763918)
- Cell-based therapies: Mesenchymal stem cell transplantation (NCT03795792)
- symptomatic trials: Novel agents for autonomic dysfunction and parkinsonism[61](https://pubmed.ncbi.nlm.nih.gov/23467654/)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
Additional evidence sources: [@kamei2008] [@lee2010] [@kahle2012] [@messmer2012] [@stefanova2015] [@dickson2010] [@peng2019] [@mollenhauer2011] [@sydow2009] [@poewe2010]
References
Wenning GK, Colosimo C, Geser F, Poewe W, Multiple system atrophy: a review of 203 pathologically proven cases (2004)
Gai WP, Blessing WW, Blumbergs PC, Lethal convective viral encephalopathy (L CVE) that resembles multiple system atrophy: a new disease? Lancet Neurol (2004)
Schrag A, Ben-Shlomo Y, Quinn NP, Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study (1999)
Klockgether T, The natural history of adult-onset olivopontocerebellar ataxia (2004)
Wuller B, Ahmed R, Bhide P, et al, A novel mutation in the GC-rich region of the alpha-synuclein gene in a family with multiple system atrophy (2010)
Wenning GK, Stefanova N, Jellinger KA, Poewe W, Scherfler C, Multiple system atrophy: a primary oligodendrogliopathy (2009)
Gilman S, Low PA, Quinn N, et al, Consensus statement on the diagnosis of multiple system atrophy (1999)
Kaufmann H, Nahm K, Purohit D, Apperley D, Autonomic failure as the initial presentation of multiple system atrophy (2004)
Stocchi F, Carbone A, Inghilleri M, et al, Urodynamic abnormalities in multiple system atrophy (2007)
Iranzo A, Santamaria J, Tolosa E, The clinical and imaging spectrum of multiple system atrophy (2009)
Ghorayeb I, Benyamin J, Tison F, Sleep related breathing disorders in multiple system atrophy: a prospective study (2009)
Papp MI, Lantos PL, The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology (1989)
Fujiwara H, Hasegawa M, Dohmae N, et al, Alpha-synuclein is phosphorylated in synucleinopathy lesions (2002)
Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M, Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies (1998)
Arawaka S, Wada M, Goto S, et al, The role of Hsp90 in the pathogenesis of multiple system atrophy (2008)
Jellinger KA, Neuropathology of multiple system atrophy: new insights into classification and pathophysiology (2004)
Dickson DW, Lin WL, Wiley CL, Hirano A, Castellani RJ, Henseling A, Neuropathology of olivopontocerebellar atrophy (2003)
Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP, Survival of patients with pathologically proven multiple system atrophy: a meta-analysis (1997)
Stefanova N, Reindl M, Neumann M, Hauser C, Schauer J, Kremer I, Microglial activation in multiple system atrophy (2009)
Kraft E, Schwarz J, Trenkwalder C, Vogl T, Fedder K, Danek A, The combination of hypointense and hyperintense lesions on MRI in multiple system atrophy (2005)
Kragh CL, Ganji S, Decet M, et al, Alpha-synuclein aggregation and neuronal cell death in multiple system atrophy (2010)
Lau A, Soh R, Kettler P, et al, Alpha-synuclein strains from multiple system atrophy and Parkinson's disease (2019)
Peng C, Trojanowski JQ, Lee VM, Protein aggregation in neurodegenerative diseases: recent insights from human brain tissue (2018)
Schapira AH, Jenner P, Etiology and pathogenesis of Parkinson's disease (2011)
Stamelou M, Lai CH, Aggarwal M, et al, Mitochondrial dysfunction in multiple system atrophy (2009)
Brodacki B, Staszewski J, Toczyłowska B, et al, Serum inflammatory cytokines in Parkinson's disease and multiple system atrophy (2008)
Bés A, Guisset C, Oertel WH, Neuroinflammation in multiple system atrophy (2010)
Villa C, Colombo G, Menach K, et al, Cyclooxygenase-2 in brain tissue of patients with multiple system atrophy (2009)
Schwarz SC,Seufferlein T,LeWitt PA, et al, Gene expression profiling in multiple system atrophy (2008)
Jellinger KA, Neuropathology of multiple system atrophy (1999)
Matsusue E, Kinoshita T, Sugii Y, Ohama E, Oguri T, Cerebellar pathology in multiple system atrophy: a comparative MRI study (2009)
Courtney E, AM K, Shapiro C, Singer W, Autonomic failure in multiple system atrophy (2009)
Riku Y, Watanabe H, Atsumi N, et al, The "hot cross bun" sign in multiple system atrophy: a comparative MRI study (2009)
Shiga K, Yamada M, Yoshikawa H, et al, MRI characteristics of the middle cerebellar peduncle in multiple system atrophy (2005)
Eckert T, Tang C, Ma Y, et al, Metabolic brain networks in multiple system atrophy: a comparative study with FDG-PET (2008)
Varrone A, Marek KL, Jennings D, et al, Striatal and cortical dopamine transporter binding in multiple system atrophy (2009)
Holmberg B, Johansson JO, Seth H, et al, Cerebrospinal fluid tau in multiple system atrophy (2001)
Fussi N, Schlörer M, Herath P, et al, Cerebrospinal fluid biomarkers in multiple system atrophy: a comparative analysis (2018)
Singer W, Schmeichel AM, Shahnawaz N, et al, Neurofilament light chain as a biomarker in multiple system atrophy (2015)
Kirchhof K, Apostolidou AN, Fowler CJ, Bladder dysfunction in multiple system atrophy: a review (2010)
Wenning GK, Tison F, Yancheva S, et al, The Movement Disorder Society criteria for the diagnosis of multiple system atrophy (2009)
Wenning GK, Geser F, Krismer F, et al, The natural history of multiple system atrophy: a prospective European study (2013)
Fanciulli A, Wenning GK, How to diagnose and treat multiple system atrophy (2015)
Low PA, Singer W, Managing autonomic dysfunction in multiple system atrophy (2008)
Wegrzynowicz M, Bar-On D, Calo L, et al, Deposition of antibodies in brain of patients with multiple system atrophy (2019)
Wagner J, Ryazanov S, Leonov A, et al, Anle138b: a novel small molecule that blocks alpha-synuclein aggregation and ameliorates disease in models of multiple system atrophy (2013)
Junn E, Lee KW, Jeong BS, et al, Repression of alpha-synuclein expression and toxicity in model systems by microRNA-7 (2009)
Beal MF, Neuroprotective effects of coenzyme Q10 in neurodegenerative diseases (2010)
Duyckaerts C, Sazdovitch V, Ando K, et al, Neuroinflammation, microglial activation, and tau pathology in multiple system atrophy (2009)
Song CH, Choi KS, Yu J, Stem cell therapy in multiple system atrophy (2015)
Fornai F, Longone P, Ferrucci M, et al, Lithium delays progression of amyotrophic lateral sclerosis (2008)
Kamei K, Tanaka A, Awata T, et al, Potential disease-modifying effects of statins in multiple system atrophy (2008)
Lee HJ, Bae EJ, Jang EH, et al, Overexpression of alpha-synuclein in oligodendrocytes leads to demyelination (2010)
Kahle PJ, Neumann M, Ozmen L, et al, Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes (2012)
Messmer K, Ravid R, Forman MS, Alpha-synuclein accumulation in oligodendrocytes in multiple system atrophy (2012)
Stefanova N, Tison F, Reindl M, Poewe W, Wenning GK, Animal models of multiple system atrophy (2015)
Dickson DW, Ahmed Z, Hassan A, et al, Neuropathology and biomarkers of progressive supranuclear palsy and corticobasal degeneration (2010)
Peng C, Gathagan RJ, Lee VM, Distinct alpha-synuclein strains and implications for neurodegeneration in multiple system atrophy (2019)
Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al, Alpha-synuclein and tau in cerebrospinal fluid as biomarkers of multiple system atrophy: a comparative study (2011)
Sydow O, Van Laar T, Van De Giessen A, Gene expression profiling in multiple system atrophy (2009)
Poewe W, Seppi K, Marconi R, et al, Efficacy of intravenous immunoglobulin in the treatment of autoimmune autonomic failure: a randomized controlled trial (2010)